🔗 Share this article

As America undertakes unprecedented changes to its immunization recommendations, one figure has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by expressing skepticism about Covid vaccinations throughout the pandemic and has focused upon possible fatalities after COVID-19 immunization in her brief time at the FDA.

Proposed Overhauls to Pediatric Vaccine Schedule

Public health authorities planned to announce radical revisions to the childhood vaccination calendar recently, synchronizing the US with the Danish vaccine program, it is understood – a substantial departure that would put the US at odds with many the global community with no evidence for benefit. The announcement has been postponed until the next year.

In place of Vinay Prasad, Tracy Beth Høeg is listed to speak at the event. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth appointee to head the office this year.

A Shift at the Regulatory Body

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine centers as Høeg and Prasad strengthen their influence at the agency – and it points to a renewed priority upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has repeatedly called for ending specific childhood vaccine recommendations in the US in order to be more in line with the Danish model, a country with comprehensive healthcare and a citizenry roughly the size of the state of Wisconsin.

So far comments, she has continued to focus on vaccination policy – traditionally the responsibility of Dr. Prasad, head of the FDA’s vaccine center – as opposed to drug regulation.

Doubts Over Background

Dr. Høeg has no apparent experience in drug development, oversight or leadership, which has been customary for past leaders of the biologics center. She has served at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for overseeing the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She has no expertise in managing a large organization. She lacks background in pharmaceutical oversight.”

Former heads of the center would “be deeply familiar with legal statutes and the science of medication creation”, noted Janet Woodcock. “Clearly, she has not acquired the type of experience that prior appointees who led the center have had.”

This division has an immense workload at the agency, she stated.

“Many people just focuses on the innovative therapies, but the generic program authorizes thousands of generic drugs. There is also a biosimilars division, over-the-counter program and other areas, and all of those need to be looked after,” she said. “The thing you neglect, that is precisely what that I always told people is going to cause problems.”

There is also, a significant management aspect to the position, which manages in excess of 5,000 staff members. “It is a huge leadership role, if you execute it properly,” the former official said.

Official Statement and Disputed Policies

In response to inquiries about Dr. Høeg's qualifications and whether this appointment represents increased cooperation among regulatory chiefs on vaccines, a press secretary responded that the “questions stem from incorrect premises”.

“Her experience is consistent with the duties of her role,” the spokesperson explained, citing the period Dr. Høeg spent advising the FDA commissioner on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg assumes responsibility for the agency head's recently launched priority voucher program, a disputed one-day medication authorization process that allegedly worried her former heads. “How are these therapies being picked for this expedited pathway? Who is making the choices?” Howard asked. “There is a lot of confidentiality occurring at the FDA right now.”

Overall, he said, “the agency looks to be trending towards more relaxed regulations of all drugs, except for vaccines.”

Documented History on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if problematic, history, some experts observe. She released a analysis using non-validated public submissions to determine the frequency of myocarditis following Covid vaccination. She advised the state of Florida surgeon general Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccines are riskier than they are.

Among her “policy goals” for the new federal leadership featured altering rules for novel immunizations and discontinuing “unnecessary” vaccines, she said post-election on a online show. At the FDA, Dr. Høeg has allegedly floated the idea of excluding teenage boys from obtaining Covid vaccines.

“She is an thorough ideologue who begins with her beliefs and tailors the evidence to fit the evidence in a very disingenuous, fraudulent fashion,” Dr. Howard argued.

Consolidating Power and a “Push for Payback”

Dr. Høeg aligned with fellow dissenters, {like|